Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) secrete deoxycytidine, which confers resistance to gemcitabine. In particular, deoxycytidine...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Exp Hematol Oncol
Autori principali: Che, Pei Pei, Gregori, Alessandro, Firuzi, Omidreza, Dahele, Max, Sminia, Peter, Peters, Godefridus J., Giovannetti, Elisa
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Letter to the Editor
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7398063/
https://ncbi.nlm.nih.gov/pubmed/32775041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00176-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi